Company Leadership - Penumbra, Inc. has announced the promotion of Shruthi Narayan to President, effective September 1, 2025, while Adam Elsesser continues as chairman and CEO [1] - Shruthi Narayan is recognized as a dynamic leader with a strong background in innovation and team inspiration, which is expected to support Penumbra's growth and market leadership [2] Professional Background - Ms. Narayan has 20 years of experience in the medical device industry, previously serving as president of Penumbra's interventional business, overseeing growth initiatives in neuro and vascular franchises [2] - She joined Penumbra in 2013 as a product manager and has played a significant role in building the company's vascular division and commercializing its thrombectomy products globally [2][3] - Narayan holds a B.S. in Electrical Engineering from Anna University, India, and an M.S. in Biomedical Engineering from the University of Southern California, focusing on Medical Device Commercialization [3] Company Overview - Penumbra, Inc. is a leading thrombectomy company focused on innovative technologies for medical conditions such as ischemic stroke and pulmonary embolism [4] - The company offers a broad portfolio, including computer-assisted vacuum thrombectomy (CAVT), aimed at improving patient outcomes and quality of life in over 100 countries [4]

Group 1 - Penumbra, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 12:30pm ET [1] - A webcast of the presentation will be available on the company's website for at least two weeks following the event [1] Group 2 - Penumbra, Inc. is a leading thrombectomy company focused on innovative technologies for medical conditions such as ischemic stroke and venous thromboembolism [2] - The company's portfolio includes computer assisted vacuum thrombectomy (CAVT) aimed at efficiently removing blood clots [2] - Penumbra supports healthcare providers in over 100 countries, enhancing patient outcomes and quality of life [2]

Core Viewpoint - Penumbra, Inc. will host a conference call to discuss its financial results for the second quarter of 2025 on July 29, 2025, at 4:30 PM Eastern Time, with a press release to follow after market close on the same day [1]. Group 1: Conference Call Details - The conference call can be accessed via phone at (888) 596-4144 with conference ID 6572573, or through a webcast available on the company's website [2]. - The webcast will remain accessible on the company's website for at least two weeks after the call [2]. Group 2: Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions such as ischemic stroke and venous thromboembolism [3]. - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently removing blood clots from various parts of the body [3]. - Penumbra supports healthcare providers in over 100 countries, striving to enhance patient outcomes and quality of life [3].

Core Insights - Penumbra, Inc. is scheduled to present at multiple investor conferences in June 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Group 1: Upcoming Events - The company will present at the William Blair 45th Annual Growth Stock Conference on June 3, 2025, at 3:00 PM ET [2]. - The Jefferies Global Healthcare Conference is scheduled for June 4, 2025, at 9:55 AM ET [2]. - The Truist Securities MedTech Conference will take place on June 17, 2025, at 10:00 AM ET [2]. Group 2: Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions like ischemic stroke and venous thromboembolism [3]. - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently removing blood clots [3]. - Penumbra operates in over 100 countries, supporting healthcare providers to enhance patient outcomes and quality of life [3].

Company Overview - Penumbra, Inc. is the world's leading thrombectomy company focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia [2] - The company's portfolio includes computer assisted vacuum thrombectomy (CAVT), aimed at removing blood clots efficiently and safely [2] - Penumbra supports healthcare providers in over 100 countries, working to improve patient outcomes and quality of life [2] Upcoming Event - Penumbra's management team is scheduled to present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 6:00 PM ET [1] - A webcast of the presentation will be available on the company's website for at least two weeks following the event [1]